dinutuximab
dinutuximab: sourced relationships with 1 company · 8 clinical trials tracked.
dinutuximab evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could dinutuximab → UTHR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| UNITED THERAPEUTICS Corp (UTHR) High-risk neuroblastoma | Approved |
Clinical Trial Registry Records (8)
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
Primary endpoint: Objective Tumor Response After One Course of Therapy
Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Primary endpoint: Best Overall Response Rate of Evaluable Patients
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Primary endpoint: Event free survival (EFS)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Primary endpoint: Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Primary endpoint: Response Rate
A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide
Primary endpoint: NK cell production feasibility (lowest dose level)
A Phase I Study of 131I-MIBG With Dinutuximab +/- Vorinostat for Relapsed/Refractory Neuroblastoma
Primary endpoint: MTD/RP2D Determination Cohort A
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Primary endpoint: Event free survival (EFS) (Arm A, B, D, and E)
Frequently asked questions
Which companies have sourced relationships with dinutuximab?
dinutuximab has dated SEC/FDA relationship records for UNITED THERAPEUTICS Corp.
How many clinical trials involve dinutuximab?
BioSniper tracks 8 clinical trials involving dinutuximab.